A Phase 3b, Multicenter, Open-label, Daratumumab Long-term Extension Study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-500138-27-01

Acronym

54767414MMY3030

Enrollment

Registered

2022-11-16

Start date

2023-02-28

Completion date

Unknown

Last updated

2025-09-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Brief summary

Primary endpoint is when no more patients require continued access to Daratumumab via this study, which means they have discontinued study treatment or have other alternative access to Daratumumab.

Interventions

DRUGImnovid 4 mg hard capsules

DRUGDEXAMETHASONE

DRUGKyprolis 60 mg powder for solution for infusion

DRUGLENALIDOMIDE

DRUGDEXAMETHASONE SODIUM PHOSPHATE

DRUGDexamethason 4 mg JENAPHARM®

DRUGDARZALEX 1800 mg solution for injection

DRUGDARZALEX 20 mg/mL concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Primary endpoint is when no more patients require continued access to Daratumumab via this study, which means they have discontinued study treatment or have other alternative access to Daratumumab.	—

Countries

Belgium, Czechia, Denmark, France, Germany, Greece, Italy, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026